CDK4/6 Inhibition With Anti-PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD-1 Alone

被引：1
|
作者：
Bose, Sminu [1 ]
Lee, Tristan [2 ]
Choi, Shaelyn [1 ]
Fazlollahi, Ladan [3 ]
Rasiej, Michael J. [4 ]
Schwartz, Gary K. [1 ]
Ingham, Matthew [1 ]
机构：
[1] Columbia Univ, Irving Med Ctr, Dept Med, Div Hematol & Med Oncol, New York, NY USA
[2] Columbia Univ, Irving Med Ctr, Dept Med, New York, NY USA
[3] Columbia Univ, Irving Med Ctr, Dept Pathol & Cell Biol, New York, NY USA
[4] Columbia Univ, Irving Med Ctr, Dept Radiol, New York, NY USA
来源：
JCO PRECISION ONCOLOGY | 2022年 / 6卷
关键词：
PEGYLATED-LIPOSOMAL DOXORUBICIN; PHASE-II; KINASE; VINCRISTINE; BLEOMYCIN; TRIAL; PD-L1; CDK6;
D O I：
10.1200/PO.21.00550
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
    Patel, Sandip P.
    Cano-Linson, Eleanor
    Chae, Young Kwang
    Schokrpur, Shiruyeh
    Lao, Christopher D.
    Powers, Benjamin C.
    Victor, Adrienne I.
    Onitilo, Adedayo A.
    Shin, Sarah
    Takebe, Naoko
    Threlkel, Sara
    Mcleod, Christine M.
    Chen, Helen X.
    Sharon, Elad
    Othus, Megan
    Ryan, Christopher W.
    Blanke, Charles D.
    Kurzrock, Razelle
    NPJ PRECISION ONCOLOGY, 2025, 9 (01)
  • [32] Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center
    Afzal, Muhammad Z.
    Shirai, Keisuke
    MELANOMA RESEARCH, 2018, 28 (04) : 341 - 347
  • [33] The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade
    Okoye, Isobel S.
    Xu, Lai
    Walker, John
    Elahi, Shokrollah
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (08) : 1423 - 1436
  • [34] The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade
    Isobel S. Okoye
    Lai Xu
    John Walker
    Shokrollah Elahi
    Cancer Immunology, Immunotherapy, 2020, 69 : 1423 - 1436
  • [35] Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
    Yadavilli, Sapna
    Waight, Jeremy D.
    Brett, Sara
    Bi, Meixia
    Zhang, Tianqian
    Liu, Yao-Bin
    Ellis, Catherine
    Turner, David C.
    Hahn, Ashleigh
    Shi, Hong
    Seestaller-Wehr, Laura
    Jing, Junping
    Xie, Qing
    Shaik, Jafar Sadik
    Ji, Xiao
    Gagnon, Robert
    Fieles, William
    Hook, Laura
    Grant, Steven
    Hopley, Stephanie
    DeYoung, M. Phillip
    Blackwell, Christina
    Chisamore, Michael
    Biddlecombe, Robert
    Figueroa, David J.
    Hopson, Christopher B.
    Srinivasan, Roopa
    Smothers, James
    Maio, Michele
    Rischin, Danny
    Olive, Daniel
    Paul, Elaine
    Mayes, Patrick A.
    Hoos, Axel
    Ballas, Marc
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (08): : 1564 - 1579
  • [36] Immunological Mechanisms behind Anti-PD-1/PD-L1 Immune Checkpoint Blockade: Intratumoral Reinvigoration or Systemic Induction?
    Guo, Zhikun
    Yu, Jiangnan
    Chen, Zihan
    Chen, Shuxian
    Wang, Lei
    BIOMEDICINES, 2024, 12 (04)
  • [37] Dramatic response to cabozantinib in patients with hyperprogression after anti-PD-1 therapy
    Schlack, K.
    Krabbe, L. -M
    Schrader, A. J.
    Klaile, Y.
    Boegemann, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 203 - 204
  • [38] Small molecule drug inhibition of PD-1 transcription is as effective as anti-PD-1 biologic blockade in cancer therapy
    Rudd, Christopher E.
    Rothstein, David
    Taylor, Alison
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [39] Intravesical anti-PD-1 immune checkpoint inhibition in urothelial bladder cancer in a mouse model
    Rajkumar, Anne
    Wang, Jian
    Neuzil, Kevin E.
    Kirschner, Austin Noah
    Chang, Sam S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [40] Can Ipilimumab restore immune response in advancedNSCLCafter progression on anti-PD-1/PD-L1agents?
    Sternschuss, Michal
    Peled, Nir
    Allen, Aaron M.
    Dudnik, Elizabeth
    Rotem, Ofer
    Kurman, Noga
    Gal, Omer
    Reches, Hiba
    Zer, Alona
    THORACIC CANCER, 2020, 11 (08) : 2331 - 2334
12345